Thiabendazole induces urinary tract toxicity in male ICR mice.
Male ICR mice were administered thiabendazole (TBZ) in the diet at concentration of 0 (control), 0.8, 1.2 and 1.6% for 44 weeks. The mortality was 10, 6, 40 or 90% in control, 0.8, 1.2 or 1.6% TBZ group, respectively. In dead mice, the gross findings included the abnormalities of kidney such as atrophy, hydronephrosis or swelling in 2, 67, 95 or 96% of the 0, 0.8, 1.2 or 1.6% TBZ group, respectively. In surviving mice at the end of study, the right kidney weight of treated groups was significantly lower than that of control group. The urinary bladder weight of treated groups was significantly higher than that of control group. Gross findings in treated mice included the renal atrophy, hydronephrosis, calculi in renal pelvis or urinary bladder and thickening of the bladder wall. Microscopic findings in the kidneys of treated mice included nephrosis, hydronephrosis and hyperplasia of transitional epithelium of renal pelvis and/or papilla. In the urinary bladder, hyperplasia or squamous metaplasia of transitional epithelium were found in treated mice. Administration of TBZ in the diet for 44 weeks results in nephrosis and calculus formation in the renal pelvis and urinary bladder of male ICR mice, and is associated with hyperplasia of transitional epithelium of renal pelvis or urinary bladder.
Tada
Y
Y
Department of Toxicology, Tokyo Metropolitan Research Laboratory of Public Health, 24-1 Hyakunincho 3-chome, Shinjuku-ku, Tokyo 169-0073-0073, Japan. info@tokyo-eiken.go.jp
Fujitani
T
T
Yano
N
N
Yuzawa
K
K
Nagasawa
A
A
Yoneyama
M
M
D000818:Animals; D000871:Anthelmintics / Q000008:administration & dosage / Q000378:metabolism / Q000633:toxicity*; D001835:Body Weight / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004435:Eating / Q000187:drug effects; D006651:Histocytochemistry; D007668:Kidney / Q000033:anatomy & histology / Q000473:pathology; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D009929:Organ Size / Q000187:drug effects; D013047:Specific Pathogen-Free Organisms; D016019:Survival Analysis; D013827:Thiabendazole / Q000008:administration & dosage / Q000378:metabolism / Q000633:toxicity*; D001743:Urinary Bladder / Q000033:anatomy & histology / Q000473:pathology; D014570:Urologic Diseases / Q000139:chemically induced*
D000871:Anthelmintics; D013827:Thiabendazole